3
H index
2
i10 index
64
Citations
Universität Wien | 3 H index 2 i10 index 64 Citations RESEARCH PRODUCTION: 19 Articles 3 Papers 1 Books 3 Chapters EDITOR: Books edited RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Jörg C. Mahlich. | Is cited by: | Cites to: |
| Journals with more than one article published | # docs |
|---|---|
| Health Economics Review | 4 |
| PLOS ONE | 2 |
| PharmacoEconomics - Open | 2 |
| Applied Health Economics and Health Policy | 2 |
| Year | Title of citing document |
|---|---|
| 2024 | Medicines prices in International (Geary–Khamis) Dollar. The comparison between regulated and deregulated markets. (2024). Kopciuch, Dorota ; Jaszcz, Paulina ; Skorupska, Patrycja ; Stolecka, Aleksandra ; Sygit, Maria ; Cynar, Julia ; Zaprutko, Tomasz ; Kus, Krzysztof ; Ratajczak, Piotr ; Paczkowska, Anna. In: PLOS ONE. RePEc:plo:pone00:0304400. Full description at Econpapers || Download paper |
| Year | Title | Type | Cited |
|---|
| Year | Title | Type | Cited |
|---|---|---|---|
| 2016 | Determinants of physicians office visits and potential effects of co-payments: evidence from Austria In: International Journal of Health Planning and Management. [Full Text][Citation analysis] | article | 1 |
| 2015 | Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG In: Perspektiven der Wirtschaftspolitik. [Full Text][Citation analysis] | article | 1 |
| 2014 | Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG.(2014) In: DICE Ordnungspolitische Perspektiven. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 1 | paper | |
| 2010 | Patents and performance in the Japanese pharmaceutical industry: An institution-based view In: Asia Pacific Journal of Management. [Full Text][Citation analysis] | article | 10 |
| 2006 | The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan In: Review of Industrial Organization. [Full Text][Citation analysis] | article | 18 |
| 2006 | The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan.(2006) In: MERIT Working Papers. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 18 | paper | |
| 2005 | Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie In: Zeitschrift für Wirtschaftspolitik. [Full Text][Citation analysis] | article | 0 |
| 2011 | Intangibles Kapital und Rentabilität in der Pharmaindustrie In: Die Unternehmung - Swiss Journal of Business Research and Practice. [Full Text][Citation analysis] | article | 1 |
| 2018 | Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data In: PLOS ONE. [Full Text][Citation analysis] | article | 0 |
| 2020 | Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study In: PLOS ONE. [Full Text][Citation analysis] | article | 0 |
| 2013 | Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 2 |
| 2013 | Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany.(2013) In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] This paper has nother version. Agregated cites: 2 | article | |
| 2022 | Estimation of Health-State Utility Values and Factors Driving Health-Related Quality of Life in People Living with HIV and AIDS and Receiving cART in Germany: Baseline Analysis of a Cohort Study In: Applied Research in Quality of Life. [Full Text][Citation analysis] | article | 0 |
| 2022 | Telemedicine in Japan: Challenges and Opportunities In: Contributions to Economics. [Citation analysis] | chapter | 0 |
| 2021 | Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis In: Health Economics Review. [Full Text][Citation analysis] | article | 0 |
| 2012 | Economic burden of osteoporotic fractures in Austria In: Health Economics Review. [Full Text][Citation analysis] | article | 1 |
| 2013 | Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment In: Health Economics Review. [Full Text][Citation analysis] | article | 0 |
| 2014 | Pharmaceutical regulation in Europe and its impact on corporate R&D In: Health Economics Review. [Full Text][Citation analysis] | article | 4 |
| 2017 | Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 0 |
| 2019 | Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 0 |
| 2007 | Introduction: Korea as a Newly Advanced Economy and the Role of Technology and Innovation In: Springer Books. [Citation analysis] | chapter | 3 |
| 2007 | The Technological Competencies of Korea’s Firms: A Patent Analysis In: Springer Books. [Citation analysis] | chapter | 1 |
| 2001 | The Changing Nature of Pharmaceutical R&D - Opportunities for Asia? In: Research Memorandum. [Full Text][Citation analysis] | paper | 1 |
| 2019 | Returns on different types of investment in the global pharmaceutical industry In: Managerial and Decision Economics. [Full Text][Citation analysis] | article | 1 |
| 2011 | R&D MANAGEMENT OF JAPANESE PHARMACEUTICAL FIRMS In: International Journal of Innovation and Technology Management (IJITM). [Full Text][Citation analysis] | article | 0 |
| 2006 | Das D-A-CH-Reformbarometer: Reformpolitik in Deutschland, Österreich und der Schweiz In: IW-Analysen. [Full Text][Citation analysis] | book | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated December, 22 2025. Contact: CitEc Team